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Abstract
Although toxic when inhaled in high concentrations, the gas carbon monoxide (CO) is 
endogenously produced in mammals, and various beneficial effects are reported. For potential 
medicinal applications and studying the molecular processes underlying the pharmacological 
action of CO, so-called CO-releasing molecules (CORMs), such as 
tricabonyldichlororuthenium(II) dimer (CORM-2), have been developed and widely used. Yet, it is 
not readily discriminated whether an observed effect of a CORM is caused by the released CO gas, 
the CORM itself, or any of its intermediate or final breakdown products. Focusing on Ca2+- and 
voltage-dependent K+ channels (KCa1.1) and voltage-gated K+ channels (Kv1.5, Kv11.1) relevant 
for cardiac safety pharmacology, we demonstrate that, in most cases, the functional impacts of 
CORM-2 on these channels are not mediated by CO. Instead, when dissolved in aqueous 
solutions, CORM-2 has the propensity of forming Ru(CO)2 adducts, preferentially to histidine 
residues, as demonstrated with synthetic peptides using mass-spectrometry analysis. For KCa1.1 
channels we show that H365 and H394 in the cytosolic gating ring structure are affected by 
CORM-2. For Kv11.1 channels (hERG1) the extracellularly accessible histidines H578 and H587 
are CORM-2 targets. The strong CO-independent action of CORM-2 on Kv11.1 and Kv1.5 
channels can be completely abolished when CORM-2 is applied in the presence of an excess of 
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free histidine or human serum albumin; cysteine and methionine are further potential targets. Off-
site effects similar to those reported here for CORM-2 are found for CORM-3, another ruthenium-
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1. Introduction
Carbon monoxide (CO) is an odorless toxic gas, typically generated during incomplete 
combustion of organic matter. However, CO is also endogenously produced in mammals 
(Tenhunen et al., 1968) and affects many processes such as vascular tone regulation 
(Coburn, 1979) and synaptic transmission (Zhuo et al., 1993). Therefore, CO may also serve 
as a physiological gaseous messenger with therapeutic potential. This aspect spurred the 
development of CO-releasing molecules (CORMs) to be used as drugs, circumventing 
complications during therapeutic inhalation of CO gas.
Among several different CORMs synthesized, tricarbonyldichlororuthenium(II) dimer 
(CORM-2; Motterlini et al., 2002), most likely because of its commercial availability, has 
been used extensively in in-vitro studies. Compared with application of CO itself, CORMs 
are safer and easier to use in experimental settings; however, a drawback of using CORMs is 
the potential problem of eliciting molecular reactions that are unrelated to CO itself but 
originate from other by-products. Unfortunately, such CORM-mediated side effects have not 
been studied systematically.
Studies utilizing CORMs have implicated numerous molecular effectors of CO (reviewed in 
e.g. Gullotta et al. 2012; Wegiel et al., 2013). For example, it is generally accepted that 
activation of large-conductance, Ca2+- and voltage-activated K+ (KCa1.1) channels 
contributes to the CO-dependent vasorelaxation (Wang et al., 1997; Williams et al., 2004). 
However, vasorelaxation induced by CO gas and CORM-2 apparently involves different 
molecular mechanisms (Decaluwé et al., 2012). Furthermore, CO-mediated activation of 
KCa1.1 channels in human umbilical vein endothelial cells is not mimicked by CORM-2 
(Dong et al., 2008).
The tetrameric KCa1.1 channels are composed of a transmembrane central pore domain 
surrounded by four voltage-sensing domains, similar to voltage-gated K+ (Kv) channels. 
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Two large cytosolic C-terminal domains (RCK1 and RCK2), which are absent in Kv 
channels, form a gating ring structure. The channel open probability is controlled by 
transmembrane voltage and the conformation of the gating ring, which changes upon 
binding of intracellular Ca2+ (Hoshi et al., 2013) or a plethora of molecules, among them 
possibly CO (Hou et al., 2009). Activating impacts of CO gas or several CORMs have been 
reported, but the underlying molecular mechanisms are still under debate. Proposed 
molecular determinants for CO effects on KCa1.1 include extracellular histidines (Wang and 
Wu, 1997), channel-bound heme (Jaggar et al., 2005), H365 and H394 within RCK1 (Hou et 
al., 2008b), and C911 within RCK2 (Williams et al., 2008; Telezhkin et al., 2011).
Here we analyzed the mechanism by which CORM-2 – as compared to CO gas – affects 
KCa1.1, Kv11.1 (hERG1) and Kv1.5 channels. We present generally applicable experimental 
strategies for identifying and avoiding side effects originating from CORM-2 and related 
CO-releasing compounds.
2. Materials and methods
2.1. Expression plasmids and mutagenesis
Wild-type human K+ channels used in this study were: KCa1.1, (hSlo1, KCNMA1, U11058), 
Kv1.5 (KCNA5, P22460), Kv10.1 (hEAG1, KCNH1, AJ0013668), Kv11.1 (hERG1, 
KCNH2, NM_000238), and Kv11.3 (hERG3, KCNH7, NP_150375). Mutations were 
introduced by overlap extension PCR (Expand High Fidelity, Roche, Mannheim, Germany), 
verified by DNA sequencing.
2.2. Cell culture
HEK 293T cells (DSMZ, Braunschweig, Germany) were maintained in DMEM/F-12 (Life 
Technologies, Darmstadt, Germany) supplemented with 10% fetal bovine serum at 37 °C in 
a humidified 5% CO2 incubator. Cells were trypsinized, diluted with culture medium, and 
seeded on 12-mm glass coverslips. Patch-clamp experiments were performed 2–3 days after 
plating. Cells were transfected with the respective plasmids using the Rotifect® (Roth, 
Karlsruhe, Germany) transfection reagent. CD8-encoding plasmids (10–20% of total DNA) 
were co-transfected to allow identification of transfected cells using anti-CD8-coated beads 
(Dynabeads, Invitrogen, Karlsruhe, Germany).
2.3. Electrophysiological measurements
Whole-cell and inside-out voltage-clamp experiments were performed as described 
previously (Gessner et al., 2010; Gessner et al., 2012). Briefly, patch pipettes with 
resistances of 1.0–2.5 MΩ were used. The series resistance was compensated for by more 
than 70% to minimize voltage errors. Patch-clamp amplifier EPC9 or EPC10 was operated 
with PatchMaster software (both HEKA Elektronik, Lambrecht, Germany). Leak and 
capacitive currents were corrected with a p/n method with a leak holding voltage of −110 
mV. Currents were low-pass filtered at 5 kHz and sampled at a rate of 25 kHz. All 
experiments were performed at 21–23 °C.
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Internal solutions contained (mM): 140 KCl, 10 EGTA, 10 HEPES (pH 7.4 with KOH). For 
whole-cell recordings the external (bath) solution consisted of (mM): 146 NaCl, 4 KCl, 2 
CaCl2, 2 MgCl2, 10 HEPES (pH 7.4 with NaOH). To allow buffering of pH between 6.5 and 
8.5, MES or TRIS was used instead of HEPES when appropriate. For inside-out recordings 
the external (pipette) solution composed of (in mM): 140 KCl, 2 CaCl2, 2 MgCl2, 10 
HEPES (pH 7.4 with KOH).
Solutions containing CO gas (1 mM) were prepared on the day of experiments by bubbling 
the solution for >20 min with CO gas and stored in gas-tight rubber-sealed glass vials. 
CORM-2 and CORM-3 aliquots were dissolved in DMSO (50 or 100 mM) vigorously 
mixed for 5 s and immediately diluted in the bath to the final concentration, resulting in a 
maximal final DMSO concentration of 0.1%. CORM-S1 and CORM-EDE1 were dissolved 
in DMSO (50 mM), aliquoted and stored at −20 °C in the dark for up to 2 months, a period 
during which no significant loss of CO-releasing activity was observed in a standard 
myoglobin assay. For CORM structures see Supplementary Fig. 1. CO release from CORM-
S1 and CORM-EDE1 was triggered by illumination of the solution in the focus of a 40× 
objective with blue light from a 100-W HBO mercury lamp (400–470 nm). CORM-2 was 
from Sigma-Aldrich (Darmstadt, Germany); iCORM-2, CORM-3, CORM-S1 and CORM-
EDE1 were synthesized according to protocols published previously (Motterlini et al., 2002; 
Johnson et al., 2007; Kretschmer et al., 2011; Mede et al., 2016).
2.4. Peptide synthesis
Solid-phase peptide synthesis was carried out on Rink amide MBHA resin (0.53 mmol/g, 
Iris) applying a standard Fmoc (9-fluorenylmethyloxycarbonyl) protocol with 2-(1H-
benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (HBTU) and 
hydroxybenzotriazole (HOBt) as coupling agents. Synthesis was performed using an 
automated peptide synthesizer EPS221 (Intavis, Cologne, Germany). Peptide cleavage was 
carried out using 1 ml of the mixture: 75 mg phenol, 25 µl ethanedithiol, 50 µl thioanisol, 50 
µl water in 1 ml trifluoroacetic acid (TFA) per 100 mg of resin. The mixture was gently 
shaken for 3 h, and then the peptide was filtered off the resin and precipitated in cold diethyl 
ether. After several washing steps using diethyl ether, the crude peptides were purified by 
semi-preparative RP-HPLC on a Shimadzu LC-8A system equipped with a C18 column 
(Knauer Eurospher 100) using 0.1% TFA in water (eluent A) and 0.1% TFA in 90% 
acetonitrile/water (eluent B) as elution system. Aliquots were prepared, lyophilized and 
stored at −20 °C.
Peptides used:
Kv11.1 wild type H-GNMEQPHMDSRIGWLHNLGDQI-NH2 (1)
Kv11.1 H578D H-GNMEQPDMDSRIGWLHNLGDQI-NH2 (2)
Kv11.1 H587Y H-GNMEQPHMDSRIGWLYNLGDQI-NH2 (3)
Kv11.1 H578D:H587Y H-GNMEQPDMDSRIGWLYNLGDQI-NH2 (4)
Control-His H-AAAAHAAAA-NH2 (5)
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Peptides or Ac-His-NHMe were dissolved in ddH2O and immediately mixed with freshly 
prepared CORM-2 (in ddH2O) solutions at different ratios (4:1 and 1:1). Mixtures were 
incubated at room temperature for different durations (15 min or 12 h), centrifuged and the 
supernatant was injected into the LC-ESI-MS system micrOTOF-Q III (Bruker Daltonics 
GmbH, Bremen, Germany) equipped with a C18 column (EC100/2 Nucleoshell RP18 
Gravity 2.7 µm column, Macherey-Nagel, Düren, Germany), and detected at 220 nm. The 
column temperature was 25 °C. Analysis of the MS data was performed using Bruker 
Compass Data Analysis 4.1 software.
2.6. Amino acid analysis
Peptide concentration was determined by amino acid analysis after hydrolyzing about 500 
µg peptide in 6 N HCl in an oxygen-free environment at 110 °C for 24 h. The hydrolysis 
product was subjected to ion exchange chromatography-based amino acid analysis in an 
Eppendorf Amino Acid Analyzer LC 3000 in comparison to an external standard 
(Laborservice Onken, Gründau, Germany). The peptide contents varied between 84.2 and 
88.9%.
2.7. Mass spectrometry
The molar mass of the precursor peptides and the reaction products was measured using a 
Dionex UltiMate 3000 LC (ThermoScientific, Dreieich, Germany) coupled to a micrOTOF-
Q III system (Bruker Daltonics). CORM-2 and peptides 1–7 or Ac-His-NHMe were 
dissolved in ddH2O and mixed to final concentrations of 12.5 µM and 50 µM, respectively. 
Samples were incubated at room temperature for ≥15 min prior to application to the LC-
MS/MS device.
2.8. Electrophysiology data analysis and statistics
Electrophysiological data were analyzed with FitMaster (HEKA Elektronik) and IgorPro 
(WaveMetrics, Lake Oswego, OR, USA). Averaged data are presented as means ± S.E.M. (n 
= number of independent measurements) unless specified otherwise. Groups of data were 
compared with a two-sided Student’s t-test assuming unequal variances followed by Holms-
Bonferroni correction. The resulting P values are specified.
3. Results
3.1. CORM-2 activates KCa1.1 channels independently of CO
Quantitative evaluation of how CORM-2 as compared to CO dissolved in the intracellular 
solution activates KCa1.1 channels was performed after transient expression of KCNMA1 
(hSlo1) in HEK 293T cells. K+ current was recorded in the inside-out patch-clamp 
configuration in the virtual absence of intracellular Ca2+ during repetitive depolarizing 
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voltage steps; the impact of 50 µM CORM-2, which should be capable of releasing up to 
300 µM CO, and that of intracellular buffer with an estimated concentration of 250 µM CO 
gas were compared.
As shown in Fig. 1A, depolarization to 100 mV produced outward currents that were 
augmented up to five-fold by the application of 50 µM CORM-2 (Fig. 1A, top). Application 
of solution containing 250 µM CO, however, had a much weaker effect (at most two-fold). 
Both effects developed with a comparable time course, reaching steady state after about 2 
min (Fig. 1B). RuCl2[DMSO]4, the final breakdown product of CORM-2 dissolved in 
DMSO (iCORM-2, see Supplementary Fig. 1), did not affect KCa1.1 currents (I/ICtrl = 0.82 
± 0.05, n = 5, P = 0.15). At this point one may conclude that CORM-2 results in a local 
concentration of CO higher than 250 µM or that CORM-2 itself or a transient intermediate is 
responsible for the current-enhancing effect. When applied to the extracellular face in the 
whole-cell configuration, CORM-2 had no activating but rather a slightly inhibiting effect 
(Supplementary Fig. 2). This result argues in favor of the molecular target being located on 
the cytoplasmic side and the effector not being CO alone because CO gas should readily 
diffuse through the membrane. Moreover, KCa1.1 activation by CORM-2 was only partially 
reversible upon washout (Supplementary Fig. 3A, B). Recording of current responses to 
voltage ramps revealed that current enhancement is voltage dependent. Analysis of the ramp 
currents yielded the half-maximal voltage (V0.5) of channel activation as robust parameter 
(Supplementary Fig. 3C); CORM-2 shifted V0.5 in the hyperpolarizing direction by up to 24 
mV in a concentration-dependent manner with an EC50 of about 15 µM and a Hill 
coefficient close to unity (Supplementary Fig. 3D).
Based on the previous report that the effect of CORM-2 in KCa1.1 channels is strongly 
diminished in a mutant lacking two regulatory histidine residues in the cytosolic gating ring 
structure (H365A:H394A; Hou et al., 2008b), we measured the impact of 50 µM CORM-2 
on KCa1.1 channels in the presence of 1 mM free histidine and found that the current 
enhancement was reduced to the level obtained with CO solution alone (Fig. 1). Consistent 
with this finding, KCa1.1 mutant H365A:H394A (HA:HA) was activated by CO solution 
much like the wild type, while the effect of CORM-2 was strongly diminished, albeit not to 
the level of CO alone (Fig. 1). We thus conclude that H365 and H394 are major – but most 
likely not the only – determinants for KCa1.1 activation by CORM-2 but not by CO, while 
CO has a minor impact on the channel by means of a different mechanism.
Cysteine at position 911 in KCa1.1 was previously suggested to be a determinant for channel 
activation by CO (Telezhkin et al., 2011). In our assay, mutant C911A was indistinguishable 
from the wild type with respect to activation by CORM-2 (P = 0.97); the impact of CO was 
smaller than for the wild type (1.16 ± 0.10 vs. 1.47 ± 0.09) but activation by CO persisted (P 
= 0.028) (Fig. 1C). Further, mutation E535A, which was shown to eliminate RCK1-
mediated channel activation by Ca2+ (Zhang et al., 2010), did not affect the impact of 
CORM-2 (P = 0.93) or CO (P = 0.87) (Fig. 1C). Elimination of RCK2-mediated channel 
activation by Ca2+ via mutation ΔCaBowl (D884 and D885 removed) (Schreiber and 
Salkoff, 1997; Hou et al., 2010) did not affect channel activation by CORM-2 (P = 0.99) but 
fully abolished current enhancement by CO gas (I/ICtrl = 0.78 ± 0.02, P = 0.00065); in fact, 
CO even diminished current through ΔCaBowl channels (P = 0.015). In summary, KCa1.1 
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channel activation by CO gas appears to involve structural components of RCK2 (including 
C911) and clearly differs from activation by CORM-2, which largely depends on histidine 
residues in RCK1.
3.2. CORM-2 potently inhibits Kv11.1 channels
The results shown above clearly demonstrate that CORM-2 application with the intention of 
delivering CO bears the potential risk of unspecific target modification, unrelated to the CO 
effect itself. We therefore asked whether other K+ channels are affected by CORM-2 
similarly as KCa1.1. Here we focused on cardiac Kv11.1 (hERG1, KCNH2) channels. 
Kv11.1 is an important target in safety pharmacology because its inhibition increases the 
risk of fatal cardiac arrhythmia (Finlayson et al., 2004). Kv11.1 channels were assayed in the 
whole-cell mode after transient expression in HEK 293T cells, and CORM-2 as well as CO-
containing bath solutions were applied to the extracellular face of the membrane. Kv11.1 
channels were activated and subsequently inactivated by 400-ms depolarizations to 20 mV; 
the peak current at 0 mV, following short recovery from inactivation at −120 mV, was 
measured and analyzed (Fig. 2A). Application of 50 µM CORM-2 strongly inhibited the 
current (to 28.2 ± 2.1% within 5 min) whereas 250 µM CO was without noticeable effect (P 
= 0.981) (Fig. 2A, B). Neither was the current blocked by application of 100 µM RuCl3 (101 
± 5%, n = 5). Like for KCa1.1, the effect of CORM-2 was completely eliminated in the 
presence of 1 mM free histidine; even 100 µM histidine was sufficient to noticeably diminish 
the activity of CORM-2 (Fig. 2C). Alanine at 1 mM, however, did not appreciably abolish 
the effect of CORM-2, while 1 mM imidazole was as effective as 100 µM histidine (Fig. 2B, 
C), indicating that the imidazole moiety of histidine likely is a receptor for CORM-2 or one 
of its breakdown products. Pre-application of 30 µM human serum albumin (HSA) also fully 
abolished CORM-2 effects on Kv11.1 (Fig. 2C), thus suggesting that systemic application of 
CORM-2 is unlikely to modify Kv11.1 channels in the heart.
3.3. Pore-loop histidines of Kv11.1 are molecular targets of CORM-2
Free or surface-exposed histidine, such as in HSA (see, e.g., PDB entry 1E78), may 
attenuate the impact of CORM-2 on Kv11.1 channels by competing as alternative molecular 
target with surface-exposed histidine residues of Kv11.1 proteins. To test whether histidines 
that were previously shown to be relevant for redox sensing of the channel (Pannaccione et 
al., 2002) are involved, we introduced the mutations H578D and H587Y: selection of 
aspartate and tyrosine to replace histidine was motivated by finding such residues at the 
equivalent positions in the closely related Kv10.1 (EAG1, KCNH1) channels (Fig. 3A). 
Elimination of these pore-loop histidines from Kv11.1 channels markedly attenuated the 
impact of 50 µM CORM-2 after 300 s: I / ICtrl = 55.3 ± 3.8% (n = 6) vs. 28.2 ± 2.1% for the 
wild type (n = 21; P < 0.001) (Fig. 3B, C). Moreover, closely related Kv11.3 (hERG3, 
KCNH7) channels, which lack the corresponding histidines, were only marginally inhibited 
by CORM-2; 72.8 ± 4.2%, n = 7 (Fig. 3B, C). In conclusion, histidine residues may serve as 
molecular targets for CORM-2 inhibition of K+ channels.
The pore-loop histidines of Kv11.1 or free or protein-bound histidines in general may serve 
as binding sites for CORM-2 or fragments thereof. We therefore synthesized 22mer peptides 
corresponding to pore-loop residues G572 to I593 of Kv11.1 (wild type (1) or histidine 
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mutants (2–4)) and studied their interaction with CORM-2 and its degradation products. 
Peptides were dissolved in water, incubated with an aqueous CORM-2 solution at a 
peptide:CORM-2 ratio of 4:1 for 15 min, and analyzed using HPLC and LC-ESI-MS/MS. 
As shown in Fig. 4A (left), CORM-2 treatment of the wild-type peptide (1) decreased the 
original peptide peak in the elution profile while additional peaks at longer elution times 
appeared, thus indicating stable peptide modifications. In contrast, neither a decrease of the 
peak of the unmodified peptide nor additional peaks upon incubation with CORM-2 were 
detected for the histidine-free peptide (4) (Fig. 4A, right). LC-ESI-MS/MS analysis (Fig. 
4B) revealed an increase in mass compatible with an attachment of Ru(CO)2 to peptide (1), 
but no modification of (4); peptides (2) and (3), i.e. those harboring only one histidine 
residue, were also subject to CORM-2 modification (Supplementary Fig. 4).
We also assessed incubation of CORM-2 with control peptide 5 ([M+H]+ 723.39 m/z) or 
with Ac-His-NHMe ([M+H]+ 211.12 m/z), which resembles a histidine with free side chain 
but protected termini. In both cases the m/z value was increased by 157.89 m/z, pointing 
towards attachment of Ru(CO)2. For Ac-His-NHMe, however, a further signal ([M
+H]+ 579.12 m/z) indicated an additional complex formed during the incubation, most likely 
a 2:1-complex of Ac-His-NHMe and Ru(CO)2. Both signals, the 1:1 and the 2:1 complex, 
respectively, increased according to the base peak chromatogram over time in approximately 
the same ratio. In contrast, a 2:1 complex of the control peptide 5 and Ru(CO)2 was not 
detected. This might be due to steric hindrance of the peptide backbone upon coordination to 
Ru(CO)2 on either coordination side.
3.4. Histidine-dependent and -independent modification of K+ channels by CORM-2
Results shown thus far indicate that pore-loop histidines are among the targets of CORM-2 
that result in a functional impact on Kv11.1 channels. Kv10.1 channels, which are closely 
related to Kv11.1, lack pore-loop histidines (Fig. 5A). However, these channels were very 
sensitive to CORM-2 (I / ICtrl = 9.0 ± 1.7%, n = 6, Fig. 5B), suggesting that other histidines 
or other residues are involved. Free histidine (1 mM) eliminated the effect of CORM-2, and 
solution with 250 µM CO had no influence on channel function (Fig. 5C). An involvement 
of histidine residue H364 within S5 of Kv10.1 could not be tested because mutations at this 
position rendered the channel nonfunctional. However, mutation of H343 at the intracellular 
end of the voltage-sensing S4 helix to arginine significantly diminished the channel’s 
sensitivity to CORM-2 (I / ICtrl = 51.0 ± 4.0%, n = 6; P = 0.00002) (Fig. 5B, C).
Kv1.5 channels, which like Kv11.1 are also expressed in the heart and therefore also 
potential targets with relevance for safety pharmacology (Schmitt et al., 2014), were also 
insensitive to CO but strongly inhibited by 50 µM CORM-2 (I / ICtrl = 8.2 ± 1.5%, n = 7; 
Fig. 5B, C). Although 1 mM free histidine fully abolished the inhibitory influence of 
CORM-2 (I / ICtrl = 93.3 ± 1.4%, n = 6), histidine residues within the channel protein 
apparently only play a minor role because a mutant channel in which all four putative target 
histidines were eliminated (mutant AARA, combining mutations H284A, H289A, H416R 
and H463A, Fig. 5A) still responded to CORM-2 (AARA: I / ICtrl = 37.2 ± 5.6%, n = 9) 
(Fig. 5B, C). Taken together, the data show that various voltage-gated K+ channels are 
insensitive to CO gas but sensitive to CORM-2. Although the CORM-2 effects on all 
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channels analyzed could be diminished by co-application of free histidine, histidines are not 
the only determinants.
3.5. pH dependence of CORM-2 modification of Kv11.1 channels
An involvement of histidines in the inhibition of Kv11.1 channels by CORM-2 suggests that 
this effect may depend on the pH value. Indeed, while 50 µM CORM-2 caused channel 
inhibition to I / ICtrl = 28% at pH 7.4, the effect was augmented at pH 6.5 (I / ICtrl = 4%) and 
virtually abolished at pH 8.5 (I / ICtrl = 105%) (Fig. 6A). A detailed analysis of the pH 
dependence revealed that CORM-2 inhibition of Kv11.1 channels is described by two pK 
values of 7.0 and 8.3 with 30% and 70% contribution, respectively (Fig. 6B). These pK 
values may correspond to the side-chain pKa values of histidine (pKa <7) and cysteine (pK 
8.3) serving as targets for modification by CORM-2. This idea is further supported by the 
small size of this pK-7 component in Kv1.5 channels (Supplementary Fig. 5), for which 
elimination of the histidine residues only partially removed the CORM-2 sensitivity (Fig. 
5B, C).
3.6. Involvement of residues other than histidine
The pH titration experiments suggest that only a fraction of CORM-2 effects on KV channels 
can be accounted for modification of histidine residues, and that cysteine might be an 
alternative target. We therefore systematically assessed the impact of different free amino 
acids (1 mM) on the potency of 50 µM CORM-2 to inhibit Kv11.1 channels. As 
demonstrated in Fig. 7, only cysteine and histidine fully abolished Kv11.1 inhibition by 
CORM-2. Nevertheless, also methionine, aspartate, and threonine had substantial impacts on 
CORM-2 activity, whereas alanine, asparagine, isoleucine, tryptophan, and proline were 
clearly without effect.
We therefore also synthesized 9mer peptides with central His (5), Ala (6), or Cys (7), 
flanked by four Ala on each side. Incubation of these peptides (each 50 µM) with CORM-2 
(12.5 µM) for 15 min and subsequent LC-MS analysis revealed that only in the His-
containing peptide Ru(CO)2 adducts could be detected as inferred from a mass increase of 
157.89 m/z (Supplementary Fig. 6). For an increased CORM-2:peptide ratio (1:1) and 
increased incubation time (12 h) histidine-independent interactions of CORM-2 with 
peptides, i.e. also with (4), were observed, thus indicating that CORM-2-induced peptide 
modifications are not specific for histidine only.
3.7. Not all metal-based CORMs cause CORM-2-like side effects
CORM-3 is ruthenium-based, where the metal ion is pre-bound to the amino acid glycine 
(Supplementary Fig. 1). However, this feature does not prevent inhibition of Kv11.1 and 
Kv1.5 channels by CORM-3, and in both cases channel inhibition was strongly diminished 
by the presence of 1 mM free histidine (Supplementary Fig. 7).
We also tested photo-CORMs with iron (CORM-S1; Kretschmer et al., 2011) or manganese 
(CORM-EDE1; Mede et al., 2016) as the metal center. Blue-light illumination of CORM-
EDE1 (100 µM), which triggers release of CO, was without effect on Kv11.1 (Fig. 8A, B) 
and Kv1.5 (Fig. 8C, D) currents. Illumination of CORM-S1 (100 µM) also failed to affect 
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Kv1.5 channels (Fig. 8C, D) but clearly inhibited Kv11.1 channels (Fig. 8A, B). This effect 
(I / ICtrl = 46.9 ± 3.9%, n = 6) was only partially attenuated by co-application of 1 mM 
histidine (I / ICtrl = 80.0 ± 3.1%, n = 3) and, hence, suggests a different molecular 
mechanism from that for CORM-2.
4. Discussion
Physiologically produced CO, mainly by the catabolism of heme catalyzed by heme 
oxygenase, is a putative cellular messenger. However, unlike NO, which has been studied 
extensively and has clearly identified molecular targets, the medicinal benefits of CO and the 
underlying molecular mechanisms are less well defined. For possible clinical applications 
and for studying CO-related biology, the local release of CO by means of CORMs is 
desirable. However, potential confounding factors must be recognized and alternative 
strategies need to be devised. We show here that CORM-2 has the propensity of forming 
Ru(CO)2 adducts to histidine side chains. For voltage-gated K+ channels the functional 
consequences are diverse: while KCa1.1 channels are activated, Kv11.1, Kv10.1, and Kv1.5 
are inhibited by CORM-2 in a CO-independent manner. These modulations involve the 
histidine residues previously identified to be important for various aspects of gating. While 
H365 and H394 in KCa1.1 affect channel regulation by intracellular pH (Hou et al., 2008a), 
the extracellular histidines in Kv11.1 (H578 and H587) are implicated in the channel’s 
regulation by iron-mediated oxidation (Pannaccione et al., 2002).
Ru(CO)2 adduct formation is largely independent of the local environment because it occurs 
with free histidine and within peptides or proteins such as HSA. In our experimental 
settings, co-application of 1 mM histidine or 30 µM HSA “quenched” adverse effects of 
CORM-2 on K+ channels. This quenching effect is consistent with the observation that 
CORM-2 does not elicit obvious cardiac side effects when administered systemically to 
rodents (Motterlini et al., 2002; Cepinskas et al., 2008). Excess HSA in the blood serving as 
scavenger for Ru(CO)2 adducts probably prevents CORM-2-dependent inhibition of Kv11.1 
and Kv1.5 channels that otherwise could result in cardiac arrhythmia (Finlayson et al., 2004; 
Schmitt et al., 2014). Vascular side effects due to activation of KCa1.1 are even less likely 
because extracellular CORM-2 did not affect these channels (Supplementary Fig. 2). 
Similarly, extracellularly applied CORM-2 does not activate KCa1.1 channels in human 
umbilical vein endothelial cells (Dong et al., 2008). The sensitivity of KCa1.1 to 
intracellularly applied CORM-2 suggests that CORM-2 or its breakdown products cannot 
cross the membrane or that they immediately react with off-site histidines on the 
extracellular side of the membrane.
Despite the rapid decomposition of CORM-2 in a physiological environment some systemic 
functional impacts may occur distant from the systemic application site. Such effects may 
originate from HSA-Ru(CO)2 complexes serving as temporary CO storage molecules. 
Compatible with this notion, binding of Ru(CO)n fragments, with n ranging from 0 to 3, 
typically to histidine, has been described (Santos-Silva et al., 2001; Santos et al., 2012; 
Seixas et al., 2015; Tabe et al., 2015; Valensin et al., 2010). Moreover, Tabe et al. (2015) 
observed CO release from ruthenium carbonyl-incorporated cross-linked hen egg white 
lysozyme (HEWL). Loss or release of a carbonyl moiety, however, does not necessarily 
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imply release of CO because CORM-3-mediated adduct formation to HEWL, HSA, and 
hemoglobin was also shown to result in the release of CO2 (Santos-Silva et al., 2011). Future 
studies must clarify whether physiological impacts resulting from systemically administered 
CORM-2 depend on the release of CO at all.
Protein modifications by CORM-2, as we have shown for KCa1.1 and Kv11.1 channels, may 
have been misinterpreted in previous studies as CO effect. In particular for KCa1.1 channels 
this resulted in contradictory models on the molecular mechanism of channel activation by 
CO (reviewed in Heinemann et al., 2014). For KCa1.1 channels we conclude that CO gas and 
CORM-2 mediate channel activation by different mechanisms, the latter requiring histidine 
residues H365 and H394 within the RCK1 domain. The impact of CO itself accounts for at 
most 20% of the channel activation observed with CORM-2. Such differences in the mode 
of action may also underlie the observed differences in vasorelaxing effects of CO vs. 
CORM-2 in vascular ring preparations (Decaluwé et al., 2012). The mechanism by which 
CO gas activates KCa1.1 channels, however, remains elusive, albeit the involvement of heme 
moieties is a likely scenario (Jaggar et al., 2005).
Conclusions from previous studies utilizing CORM-2 and related compounds to elucidate 
the molecular mechanism of CO action need to be revisited because iCORM-2 
(Supplementary Fig. 1) and hemoglobin may not be proper controls for distinguishing 
between CO gas effects and formation of Ru(CO)2 adducts. Hemoglobin binds CO, but it 
may also simultaneously serve as an acceptor for Ru(CO)2 adducts via surface-exposed 
histidines. iCORM-2 may be a proper control if it exerts a similar effect as CORM-2, such 
as observed for the inhibition of Kv2.1 channels (Jara-Oseguera et al., 2011).
We also noticed quenching of CORM-2 effects by free cysteine and methionine (Fig. 7). 
Similar to sulfite species (McLean et al., 2012), these amino acids may serve as 
physiological triggers to initiate CO release from CORM-2. Assuming such a mechanism, 
the observed quenching of the CORM-2 side effect might be explained by induced 
decomposition of CORM-2 such that no Ru(CO)2 adducts to histidine can be formed. 
Alternatively, cysteine or methionine may serve as acceptors for binding of Ru(CO)n 
fragments. However, we did not observe Ru(CO)2 adducts for cysteine-containing peptides 
(Supplementary Fig. 6). This finding may be explained by either very weak binding or the 
necessity of a secondary amino acid that was not present in our peptide assay. The latter was 
experimentally observed in a ferritin / CORM-2 composite in which Ru(CO)2 adduction to 
cysteine required a glutamate residue (Fujita et al., 2014).
Tavares et al. (2011) suggested that CORM-2 stimulates ROS production in E. coli, which 
amplifies the cytotoxic effect (Nobre et al., 2007) of CO gas, an effect that can be quenched 
by co-application of hemoglobin or antioxidants including GSH, free cysteine, and 
methionine. In fact, part of the Kv11.1 response to CORM-2 in the presence of 1 mM 
histidine was a small but significant increase in current (Fig. 2B), which was strongly 
diminished by mutagenesis of extracellular histidines (mutant Kv11.1-H578D:H587Y) 
(Supplementary Fig. 8). This effect is reminiscent of a transient current increase when 
applying H2O2 to Kv11.1 channels (Kolbe et al., 2010) and, hence, indicates that oxidation 
or protonation of the histidine residues may also take place on CORM-2 application.
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Metal- or metal-carbonyl-based side effects are not expected when using transition metalfree 
CORMs such as CORM-A1 (Motterlini et al., 2005; Supplementary Fig. 1) or more recently 
developed metal-free CORMs (e.g., Palao et al., 2016; Ji et al., 2017). Among the metal-
based CORMs, metal-carbonyl adduct formation is not specific for ruthenium but was also 
observed for iridium (Catarino et al., 2016). We found that the iron-based CORM-S1, 
despite being without effect on Kv1.5, inhibits Kv11.1 channels when decomposed with 
blue light (Kretschmer et al., 2011). In fact, application of the expected final breakdown 
products CO and cysteamine alone had no effects on Kv11.1 channels, and application of 
Fe2+ alone inhibited Kv11.1 channels with at least 20-fold slower kinetics (Supplementary 
Fig. 9). Our experiments with manganese-based CORM-EDE1 (Mede et al., 2016) gave no 
indication for similar side effects on Kv11.1 and Kv1.5 channels (Fig. 8). Manganese-based 
CORMs may therefore represent attractive alternatives for physiological tests, in particular 
when CO release is triggered with visible light.
In conclusion, due to multiple side effects elicited by decomposing metal-based CORMs, a 
direct proof for the involvement of the released CO gas in functional assays is not 
straightforward. In future experiments utilizing CORMs as source of CO, in particular under 
conditions with inorganic buffers, great care regarding the derived conclusions on the impact 
of CO is warranted. Application of CO gas itself remains the gold standard in physiological 
experiments for testing whether or not CORM effects are to be associated with the action of 
the gaseous messenger CO.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. Activation of KCa1.1 channels by CORM-2 and CO
A) Current traces in response to the indicated pulse protocol recorded from inside-out 
membrane patches of HEK 293T cells expressing KCa1.1 wild type (wt) or mutant 
H365A:H394A (HA:HA) before (black) and 3 min after the application of either 50 µM 
CORM-2, 250 µM CO, or 50 µM CORM-2 in the presence of 1 mM histidine (colored). B) 
Time courses of the normalized steady-state current with 50 µM CORM-2 (without and with 
1 mM histidine) or 250 µM CO application at time zero. Straight lines connect data points 
for clarity. C) Mean steady-state current increases by 50 µM CORM-2 (red) and 250 µM CO 
(green) for the indicated channel types and conditions. Data in B and C are means ± S.E.M. 
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with n indicated in parentheses. Asterisks indicate difference to respective wild-type data: 
*P<0.05; **P<0.01; ***P<0.001.
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Fig. 2. Inhibition of Kv11.1 channels by CORM-2
A) Whole-cell Kv11.1 currents elicited with the indicated voltage protocol before (black) 
and 5 min after addition of 250 µM CO or 50 µM CORM-2 in the absence and presence of 1 
mM histidine. Depolarization to 20 mV lasted 400 ms (not shown). B) Maximal outward 
current amplitudes at 0 mV as a function of time, normalized to the level before application 
of 50 µM CORM-2 at time zero with 1 mM of the indicated substances in the bath solution: 
His, histidine; Im, imidazole; Ala, alanine. Straight lines connect data points for clarity. C) 
Normalized remaining current after 5 min application of 50 µM CORM-2 plus the 
competing compounds, as indicated (HSA, human serum albumin). Data in B and C are 
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means ± S.E.M. with n indicated in parentheses of C. Asterisks indicate difference to 
control, i.e. for application of 50 µM CORM-2 only (***P<0.001).
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Fig. 3. Impact of CORM-2 on Kv11.1 mutant and Kv11.3
A) Multiple sequence alignment of part of the S5–S6 loop of Kv11.1, Kv10.1, and Kv11.3; 
histidines in Kv11.1 that were mutated are highlighted. B) Representative current traces for 
the indicated pulse protocols for Kv11.1-HD:HY (Kv11.1-H578D:H587Y, left) and Kv11.3 
(right) channels in the whole-cell configuration before (black) and 300 s after application of 
50 µM CORM-2 (red). C) Mean relative remaining current for the indicated channel variants 
after CORM-2 application. Data are means ± S.E.M. with n indicated in parentheses; 
***P<0.001 difference compared with hERG1 (wild type).
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Fig. 4. Peptide modification by CORM-2
A) HPLC elution profiles of 22mer peptides corresponding to the pore loop sequences of 
wild-type Kv11.1 channels (wt, (1)) or its double mutant H578D:H587Y (HD:HY, (4)). 
Colored traces are from peptides preincubated with CORM-2, black: peptides without 
preincubation. The elution peak for the non-modified peptides is marked with an asterisk. B) 
Mass spectra of wild-type and double-mutant peptides (as in (A)) before (black) and after 
incubation with CORM-2 (red). The labeled peaks correspond to (M+4H+)4+, (M+3H+)3+ 
and (M+2H+)2+ of the peptides or the peptide:Ru(CO)2 complexes.
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Fig. 5. CO-independent inhibition of K+ channels by CORM-2
A) Membrane topology of α subunits of Kv10.1 (left) and Kv1.5 (right) channels with those 
histidine residues that are potentially accessible from the extracellular side highlighted. B) 
Representative whole-cell current traces before (black) and after (red) application of 50 µM 
CORM-2 for wild-type channel constructs (top) and mutants in which Ala or Arg was 
replaced for His: Kv10.1-H343R (blue dot in the cartoon), Kv1.5-AARA. C) Mean 
normalized remaining current after application of 50 µM CORM-2 without (red) and with 1 
mM free histidine (blue) or in 250 µM CO-containing solutions (green) for the indicated 
channel types. Asterisks indicate difference to the respective control (application of 
Gessner et al. Page 22













CORM-2 only; **P<0.01; ***P<0.001). Data are means ± S.E.M. with n indicated in 
parentheses.
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Fig. 6. pH dependence of Kv11.1 inhibition by CORM-2
A) Representative traces of whole-cell Kv11.1 currents before (black) and 5 min after (red) 
application of 50 µM CORM-2 at pH 6.5 and pH 8.5. B) Normalized mean remaining 
current after CORM-2 application as a function of pH, fit with a two-component Hill 
function (solid line). Resulting pK values are indicated by vertical bars. Data in B are means 
± S.E.M. for n = 5–21.
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Fig. 7. Influence of free amino acids on Kv11.1 inhibition by CORM-2
Mean remaining Kv11.1 current 5 min after co-application of 50 µM CORM-2 and 1 mM of 
the indicated amino acids. Asterisks indicate P values compared to application of CORM-2 
only (dashed line). Data are means ± S.E.M. with n indicated in parentheses. *P<0.05; **P< 
0.01; ***P<0.001 for tests versus CORM-2 alone.
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Fig. 8. Influence of the photo-CORMs CORM-S1 and CORM-EDE1 on Kv11.1 and Kv1.5 
channels
A) Representative whole-cell current traces of Kv11.1 channels for the pulse protocol shown 
on top before (black) and after blue-light illumination of 100 µM CORM-S1 (brown) or 100 
µM CORM-EDE1 (blue) present in the bath solution. B) Time course of mean normalized 
currents as in A with an indication of the illumination protocol. C, D) As in A and B for 
Kv1.5 channels. Data in B and D are means ± S.E.M. with n indicated in parentheses; 
straight lines connect the data points for clarity.
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